aabb-logo-sm

#AABB24: Vitalant, Dark Horse Consulting Join Biotherapies Pavilion at 2024 AABB Annual Meeting

July 25, 2024

AABB is pleased to announce that Vitalant and Dark Horse Consulting will join the Biotherapies Pavilion at the 2024 AABB Annual Meeting, taking place Oct. 19-22 in Houston, Texas.

Vitalant, an AABB corporate partner based in Arizona, is one of the nation’s largest nonprofit blood and biotherapies health care organizations. Dark Horse Consulting is a specialized firm that provides expert consulting services to the cell and gene therapy industry, focusing on technical, regulatory and strategic support to accelerate the development and commercialization of advanced therapies.

These companies join several other participating organizations in the 2024 Biotherapies Pavilion and networking space:

  • Abbott, an AABB corporate partner and a presenting sponsor of the 2024 Biotherapies Pavilion.
  • Versiti, an AABB institutional member based in Wisconsin.
  • Eurofins CellTx, an FDA-registered laboratory for screening human cells, tissues, and cellular- and tissue-based products (HCT/Ps) based in Arizona.  

Back by popular demand, the Biotherapies Pavilion is a specially designed networking space within the Exhibit Hall to provide biotherapies companies with new and curated opportunities to connect with key audiences and gain access to all that the AABB Annual Meeting has to offer.

Returning to the Biotherapies Pavilion this year are industry expert open-mic conversations. A highlight from the 2023 meeting, these engaging 45-minute events drew audiences of up to 50 people for unscripted and interactive conversations focusing on a range of biotherapies topics. Speakers from the 2023 Biotherapies Pavilion included the following:

  • Becky Cap, senior vice president of biotherapies at Vitalant, who discussed the importance of collaborations within the biotherapies ecosystem.  
  • Rob Tressler, PhD, MS, chief scientific officer at Excellos, who discussed considerations around healthy donor characterization.
  • Tracey Hlucky, quality assurance senior manager at Kite Pharma, who explored how to leverage established quality systems when developing advanced biotherapies.

This year’s open-mic sessions will focus on the cell and gene therapy workforce, advanced therapy product transport, artificial intelligence in GXP settings and more.

AABB is offering limited availability Biotherapies Pavilion connection packages and sponsorship opportunities and encourages interested organizations to register their interest while availability lasts.